Simultaneous tumors: ovarian cancer in a patient with multiple myeloma

Abstract

Multiple myeloma is the second most common hematological malignancy, accounting for approximately 1% and 10–15% of malignant tumors of the hematopoietic and lymphoid systems, respectively. Until recently, the diagnosis of multiple myeloma was inherently associated with unfavorable prognosis of overall survival. On the one hand, advanced diagnosis techniques and the development of new treatment approaches have led to the improved life expectancy and significant reduction of mortality of patients with multiple myeloma. On the other hand, the medical and research communities have encountered a previously unknown issue: the combination of multiple myeloma with other types of cancer. This combination sets a task of multidisciplinary approach in the diagnosis and requires development of patient management strategy and prognostic parameters of the outcome. Some researchers adhere to the theory of independent tumor appearance in patients suffering from multiple myeloma, while other authors suppose that multiple myeloma and secondary cancer virtually represent multiple primary malignant neoplasms. This article presents a clinical case of postmortem verification of ovarian cancer in a patient with recurrent multiple myeloma.

Keywords

simultaneous tumors / multiple myeloma / ovarian cancer / chemotherapy / clinical case

References

[1] Kaprin AD, Starinsky VV, Petrova GV, editors. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: P.A. Herzen Moscow State Medical Research Institute — branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of the Russian Federation; 2018. (In Russ.)

[2] Злокачественные новообразования в России в 2017 году (заболеваемость и смертность) / под. ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.

[3] Kaprin AD, Starinsky VV, Petrova GV, editors. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: P.A. Herzen Moscow State Medical Research Institute — branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of the Russian Federation; 2018. (In Russ.)

[4] Dong HH, Li J, Kang L, et al. Simultaneous multiple myeloma and non-small cell lung carcinoma: A case report and review of the literature. Oncol Lett. 2022;23(6):195. doi: 10.3892/ol.2022.13315

[5] Dong H.H., Li J., Kang L., et al. Simultaneous multiple myeloma and non-small cell lung carcinoma: A case report and review of the literature // Oncol Lett. 2022. Vol. 23, N 6. P. 195. doi: 10.3892/ol.2022.13315

[6] Dong HH, Li J, Kang L, et al. Simultaneous multiple myeloma and non-small cell lung carcinoma: A case report and review of the literature. Oncol Lett. 2022;23(6):195. doi: 10.3892/ol.2022.13315

[7] Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2

[8] Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms // Leukemia. 2022. Vol. 36, N 7. P. 1720–1748. doi: 10.1038/s41375-022-01620-2

[9] Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2

[10] Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35. doi: 10.1007/978-3-540-85772-3_2

[11] Becker N. Epidemiology of multiple myeloma // Recent Results Cancer Res. 2011. Vol. 183. P. 25–35. doi: 10.1007/978-3-540-85772-3_2

[12] Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35. doi: 10.1007/978-3-540-85772-3_2

[13] Raluy M, Ramagopalan S, Panjabi S, Lambrelli D. Epidemiology and clinical characteristics of patients with multiple myeloma in the United Kingdom. Blood. 2014;124(21):2048. doi: 10.1182/blood.V124.21.2048.2048

[14] Raluy M., Ramagopalan S., Panjabi S., Lambrelli D. Epidemiology and clinical characteristics of patients with multiple myeloma in the United Kingdom // Blood. 2014. Vol. 124, N 21. P. 2048. doi: 10.1182/blood.V124.21.2048.2048

[15] Raluy M, Ramagopalan S, Panjabi S, Lambrelli D. Epidemiology and clinical characteristics of patients with multiple myeloma in the United Kingdom. Blood. 2014;124(21):2048. doi: 10.1182/blood.V124.21.2048.2048

[16] Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567. doi: 10.1002/ajh.25791

[17] Rajkumar S.V. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management // American Journal of Hematology. 2020. Vol. 95, N 5. P. 548–567. doi: 10.1002/ajh.25791

[18] Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567. doi: 10.1002/ajh.25791

[19] Liu R, Gao Q, Foltz SM, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 2021;12(1):2559. doi: 10.1038/s41467-021-22804-x

[20] Liu R, Gao Q, Foltz SM, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma // Nat Commun. 2021. Vol. 12, N 1. P. 2559. doi: 10.1038/s41467-021-22804-x

[21] Liu R, Gao Q, Foltz SM, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 2021;12(1):2559. doi: 10.1038/s41467-021-22804-x

[22] Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–942. doi: 10.1016/S1470-2045(14)70282-7

[23] Sant M., Minicozzi P., Mounier M., et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study // Lancet Oncol. 2014. Vol. 15, N 9. P. 931–942. doi: 10.1016/S1470-2045(14)70282-7

[24] Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–942. doi: 10.1016/S1470-2045(14)70282-7

[25] Kaiser MF, Croft J, Shah P, et al. Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment. Br J Haematol. 2020;189(1):e1–3. doi: 10.1111/bjh.16393

[26] Kaiser M.F., Croft J., Shah P., et al. Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment // Br J Haematol. 2020. Vol. 189, N 1. P. e1–3. doi: 10.1111/bjh.16393

[27] Kaiser MF, Croft J, Shah P, et al. Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment. Br J Haematol. 2020;189(1):e1–3. doi: 10.1111/bjh.16393

[28] Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506. doi: 10.1038/bcj.2016.114

[29] Jones J.R., Cairns D.A., Gregory W.M., et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial // Blood Cancer J. 2016. Vol. 6, N 12. P. e506. doi: 10.1038/bcj.2016.114

[30] Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506. doi: 10.1038/bcj.2016.114

[31] Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121–1125. doi: 10.1056/NEJM197011192832101

[32] Kyle R.A., Pierre R.V., Bayrd E.D. Multiple myeloma and acute myelomonocytic leukemia // N Engl J Med. 1970. Vol. 283, N 21. P. 1121–1125. doi: 10.1056/NEJM197011192832101

[33] Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121–1125. doi: 10.1056/NEJM197011192832101

[34] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer Journal for Clinicians. 2019;69(1):7–34. doi: 10.3322/caac.21551

[35] Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019 // CA Cancer J Clin. 2019. Vol. 69, N 1. P. 7–34. doi: 10.3322/caac.21551

[36] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer Journal for Clinicians. 2019;69(1):7–34. doi: 10.3322/caac.21551

[37] Wang Y, Li F, Luo J, et al. Testicular plasmacytoma: a case report and review of the literature. Chin Med J. 2008;121(10):956–958.

[38] Wang Y., Li F., Luo J., et al. Testicular plasmacytoma: a case report and review of the literature // Chin Med J. 2008. Vol. 121, N 10. P. 956–958

[39] Wang Y, Li F, Luo J, et al. Testicular plasmacytoma: a case report and review of the literature. Chin Med J. 2008;121(10):956–958.

[40] Morariu I, Burns P, Roche P, Hone S. Triple manifestation of extramedullary plasmacytoma in the upper airway: an unusual clinical entity. J Laryngol Otol. 2011;125(9):970–972. doi: 10.1017/s0022215111001046

[41] Morariu I., Burns P., Roche P., Hone S. Triple manifestation of extramedullary plasmacytoma in the upper airway: an unusual clinical entity // J Laryngol Otol. 2011. Vol. 125, N 9. P. 970–972. doi: 10.1017/s0022215111001046

[42] Morariu I, Burns P, Roche P, Hone S. Triple manifestation of extramedullary plasmacytoma in the upper airway: an unusual clinical entity. J Laryngol Otol. 2011;125(9):970–972. doi: 10.1017/s0022215111001046

[43] Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330. doi: 10.1093/annonc/mdp329

[44] Varettoni M., Corso A., Pica G., et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients // Ann Oncol. 2010. Vol. 21, N 2. P. 325–330. doi: 10.1093/annonc/mdp329

[45] Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330. doi: 10.1093/annonc/mdp329

[46] Gagelmann N, Eikema D, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890–897. doi: 10.3324/haematol.2017.178434

[47] Gagelmann N., Eikema D., Iacobelli S., et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT // Haematologica. 2018. Vol. 103, N 5. P. 890–897. doi: 10.3324/haematol.2017.178434

[48] Gagelmann N, Eikema D, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890–897. doi: 10.3324/haematol.2017.178434

[49] Mirandola L, Nguyen DD, Rahman RL, et al. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol. 2014;33(5):417–27. doi: 10.3109/08830185.2014.911855

[50] Mirandola L., Nguyen D.D., Rahman R.L., et al. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? // Int Rev Immunol. 2014. Vol. 33, N 5. P. 417–427. doi: 10.3109/08830185.2014.911855

[51] Mirandola L, Nguyen DD, Rahman RL, et al. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol. 2014;33(5):417–27. doi: 10.3109/08830185.2014.911855

[52] Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011;365(23):2241–2242. doi: 10.1056/NEJMc1111010

[53] Landgren O., Thomas A., Mailankody S. Myeloma and second primary cancers // N Engl J Med. 2011. Vol. 365, N 23. P. 2241–2242. doi: 10.1056/NEJMc1111010

[54] Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011;365(23):2241–2242. doi: 10.1056/NEJMc1111010

[55] Schor APT, Moraes MPT, Bisson FW, et al. Primary plasmacytoma of the cervix in a 21-year-old female patient. Int J Gynecol Pathol. 2010;29(3):290–293. doi: 10.1097/PGP.0b013e3181c070b4

[56] Schor A.P.T., Moraes M.P.T., Bisson F.W., et al. Primary plasmacytoma of the cervix in a 21-year-old female patient // Int J Gynecol Pathol. 2010. Vol. 29, N 3. P. 290–293. doi: 10.1097/PGP.0b013e3181c070b4

[57] Schor APT, Moraes MPT, Bisson FW, et al. Primary plasmacytoma of the cervix in a 21-year-old female patient. Int J Gynecol Pathol. 2010;29(3):290–293. doi: 10.1097/PGP.0b013e3181c070b4

[58] Curtis RE, Freedman DM, Ron E, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.

[59] Curtis R.E., Freedman D.M., Ron E., et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.

[60] Curtis RE, Freedman DM, Ron E, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.

[61] Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585–598. doi: 10.1038/nrc2189

[62] Hideshima T., Mitsiades C., Tonon G., et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets // Nat Rev Cancer. 2007. Vol. 7, N 8. P. 585–598. doi: 10.1038/nrc2189

[63] Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585–598. doi: 10.1038/nrc2189

[64] Osserman EF, Takatsuki K, Talal N. Multiple myeloma I. the pathogenesis of ‘amyloidosis’. Semin Hematol. 1964;1:3–85.

[65] Osserman E.F., Takatsuki K., Talal N. Multiple myeloma I. The pathogenesis of ‘amyloidosis’ // Semin Hematol. 1964. Vol. 1. P. 3–85.

[66] Osserman EF, Takatsuki K, Talal N. Multiple myeloma I. the pathogenesis of ‘amyloidosis’. Semin Hematol. 1964;1:3–85.

[67] Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS). Blood. 2011;118(15):4086–4092. doi: 10.1182/blood-2011-05-355743

[68] Mailankody S., Pfeiffer R.M., Kristinsson S.Y., et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS) // Blood. 2011. Vol. 118, N 15. P. 4086–4092. doi: 10.1182/blood-2011-05-355743

[69] Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS). Blood. 2011;118(15):4086–4092. doi: 10.1182/blood-2011-05-355743

[70] Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship — genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98(1):15–25. doi: 10.1093/jnci/djj001

[71] Travis L.B., Rabkin C.S., Brown L.M., et al. Cancer survivorship — genetic susceptibility and second primary cancers: research strategies and recommendations // J Natl Cancer Inst. 2006. Vol. 98. N 1. P. 15–25. doi: 10.1093/jnci/djj001

[72] Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship — genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98(1):15–25. doi: 10.1093/jnci/djj001

RIGHTS & PERMISSIONS

Eco-Vector